Trials / Terminated
TerminatedNCT04753658
Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib
REAL WORLD DATA COLLECTION AMONG PEDIATRIC NEUROBLASTOMA PATIENTS TREATED WITH LORLATINIB THROUGH EXPANDED ACCESS PROGRAM
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 15 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 0 Years
- Healthy volunteers
- Not accepted
Summary
The overall goal of this real-world data collection is to assess demographic, clinical characteristics and real-world effectiveness of pediatric neuroblastoma patients treated with lorlatinib through the expanded access program.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | lorlatinib | Oral |
Timeline
- Start date
- 2021-03-19
- Primary completion
- 2022-09-30
- Completion
- 2022-09-30
- First posted
- 2021-02-15
- Last updated
- 2024-09-23
- Results posted
- 2024-09-23
Locations
11 sites across 6 countries: United States, Australia, New Zealand, Portugal, South Korea, Sweden
Source: ClinicalTrials.gov record NCT04753658. Inclusion in this directory is not an endorsement.